Reports Progress in Space-Based Cellular Broadband ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Despite these early signs of spring, it doesn’t officially begin until I can hear the neighborhood children playing in the ...

Being drafted as a 9th round senior sign isn’t an auspicious start to ... He’s the #1 prospect in baseball by most accounts (discounting Roki Sasaki, who’s technically a prospect at 23 ...

As Uzbekistan looks to meet growing gas demand while phasing out inefficient Soviet-era power facilities, a DFI/ECA-backed ...

A historic landmark, the restaurant will reopen this fall after years of extensive renovations. The updates preserve its ...

Join the Michigan Bluebird Society for the 2025 Spring Bluebird Festival on March 15 to celebrate and learn about the Eastern ...

Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...

David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing The transaction is expected to close in the first half of 2025 At the closing of the ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Bluebird Bio and its three approved lentiviral gene therapies are being acquired by investment firms Carlyle and SK Capital for less than US$30 million. The biotech had a market capitalization of ...